Pharmacogenetic Testing in Primary Care
The purpose of this study is to further integrate pharmacogenetic (PGx) testing into clinical practice by educating physicians about pharmacogenetics and offering testing to their patients. Pharmacogenetic testing may help physicians choose the best drug and dosage for their patients which can reduce side effects, increase effectiveness, and improve patient adherence.
Two clinics will be involved. One clinic will have a pharmacist on-site as a resource to physicians and to advise what patients may benefit from PGx testing; the other clinic will have a pharmacist on call.
Patient and physician perspectives about PGx testing and their utilization will be examined via surveys.
The investigators hypothesize that with education about PGx testing, more physicians will utilize testing.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Delivery of Pharmacogenetic Testing in a Primary Care Setting|
- Use of PGx testing [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: No ]
- Number of adverse drug reactions [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||December 2012|
|Estimated Study Completion Date:||July 2015|
|Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01600846
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27708|
|Principal Investigator:||Susanne Haga, PhD||Duke Unviersity Medical Center|